From employing AI trading algorithms to watching somebody yell "buy, buy, buy", investors are always looking for a leg up. Some even track certain politicians' trades, but the lag time in identifying those investments usually causes the little guys to miss out on much of the upswing and, in some cases, become the politicians' de facto exit strategy.
While not perfect, a better system, for most investors, is to follow the SEC Form 4 reports, which tracks reported insider trading. After all, who knows more about a Company's prospects than the Company's insiders?
Of course, this system isn't foolproof, like when a possible member of a 10% owner group, purchased 490,000 shares of
Just this morning, Musk, in a letter to Twitter, repeated his demand for Twitter to provide the information needed for Musk to perform necessary due diligence on determining a true buyout valuation for the social media communications platform. Musk has been trying to determine how many Twitter accounts are fake or spam bots and has requested this data from Twitter, in order to move forward with a buyout deal and he considers nondelivered data a "clear material breach" of the transaction.
It goes without stating that insiders, like just about every investor on the planet, invest to make a profit. So they're looking for value and the biotech-stock selloff, which Bloomberg recently reported "has run so far that many companies are now worth less than the amount of cash they have in the bank", has created fertile investing space, with biotech insiders being among the most active sectors.
The clinical-stage biopharmaceutical company is developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body. It's scheduled to present at the
Insiders purchased 1,751,754 in 10 transactions and sold 438,824 shares in 5 transactions, during the last 6 months.
The biopharmaceutical company is focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases and highlights of its recent Q1 2022 report include that it had
"In the first quarter of 2022, we made good progress on our strategic objectives for the year," stated
Also presenting at the upcoming
The clinical-stage genomic medicine company filed an SEC Form 4 report, for a director who purchased 5,000 shares last week, bringing their total shares to 48,700. Overall insider activity for the last 6 months is 15 purchases of 605,500 total shares versus 4 sales totaling 236,203 shares.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
DISCLAIMER:
24/7 MARKET NEWS ("24/7 MN") is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Materials in this release are informational and should never be considered research. You must do your own due diligence by reading all available public information. This release is a corporate public statement, and believed to be reliable. The principle editor of 24/7 has been compensated for the release of this press article by
Editor@247marketnews.com
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
CONTACT: editor@247marketnews.com
.
(C) 2022 M2 COMMUNICATIONS, source